UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent model

Bioorganic & medicinal chemistry letters, 2018-06, Vol.28 (10), p.1958-1963

2018

Volltextzugriff (PDF)

Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats

Journal of applied physiology (1985), 2012-06, Vol.112 (11), p.1940-1948

2012

Volltextzugriff (PDF)

Discovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7962-7965

2009

Volltextzugriff (PDF)

Discovery of 4‑Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38

Journal of medicinal chemistry, 2015-09, Vol.58 (17), p.7021-7056

2015

Volltextzugriff (PDF)

Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines

Drug metabolism and disposition, 2008-02, Vol.36 (2), p.380

2008

Volltextzugriff (PDF)

In Vitro Metabolism of Phenoxypropoxybiguanide Analogues in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines

Journal of medicinal chemistry, 2005-04, Vol.48 (8), p.2805-2813

2005

Volltextzugriff (PDF)

Proteome-wide muscle protein fractional synthesis rates predict muscle mass gain in response to a selective androgen receptor modulator in rats

American journal of physiology: endocrinology and metabolism, 2016-03, Vol.310 (6), p.E405-E417

2016

Volltextzugriff (PDF)

Identification and Characterization of 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a Selective and Irreversible Peroxisome Proliferator-Activated Receptor δ (PPARδ) Antagonist

Journal of medicinal chemistry, 2010-02, Vol.53 (4), p.1857-1861

2010

Volltextzugriff (PDF)

Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method

Journal of cachexia, sarcopenia and muscle, 2013-09, Vol.4 (3), p.217-223

2013

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Hydrolysis of Oral Pyrroloquinazolinediamines Administered in Single and Multiple Doses in Rats

Antimicrobial Agents and Chemotherapy, 2007-08, Vol.51 (8), p.2898-2904

2007

Volltextzugriff (PDF)

Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D 3 -creatine dilution method

Journal of cachexia, sarcopenia and muscle, 2013-09, Vol.4 (3), p.217-223

2013

Volltextzugriff (PDF)

Adenosine A1 Receptor Modulation of MMP-2 Secretion by Trabecular Meshwork Cells

Investigative ophthalmology & visual science, 2002-09, Vol.43 (9), p.3016-3020

2002

Volltextzugriff (PDF)

The role of in vitro ADME assays in antimalarial drug discovery and development

Combinatorial chemistry & high throughput screening, 2005-02, Vol.8 (1), p.89

2005

Volltextzugriff (PDF)

Bradykinin enhancement of PGE2 signalling in bovine trabecular meshwork cells

Experimental eye research, 2003-03, Vol.76 (3), p.283-289

2003

Volltextzugriff (PDF)

Longitudinal determination of total body creatine pool size and skeletal muscle mass in rats by D 3 ‐creatine dilution

The FASEB journal, 2013-04, Vol.27 (S1)

2013

Volltextzugriff (PDF)

Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-d3) dilution in rats

Journal of applied physiology (1985), 2012, Vol.112 (6), p.1940-1948

2012

Volltextzugriff (PDF)

Identification and Characterization of 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethylbenzamide (GSK3787), a Selective and Irreversible Peroxisome Proliferator-Activated Receptor δ (PPARδ) Antagonist

Journal of medicinal chemistry, 2010, Vol.53 (4), p.1857-1861

2010

Volltextzugriff (PDF)

Bradykinin enhancement of PGE 2 signalling in bovine trabecular meshwork cells

Experimental eye research, 2003, Vol.76 (3), p.283-289

2003

Volltextzugriff (PDF)

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist

The Journal of pharmacology and experimental therapeutics, 2011-10, Vol.339 (1), p.24

2011

Volltextzugriff (PDF)

Prediction of cochlear implant performance by genetic mutation: The spiral ganglion hypothesis

Hearing research, 2012-10, Vol.292 (1-2), p.51-58

2012

Volltextzugriff (PDF)

Advancing genetic testing for deafness with genomic technology

Journal of medical genetics, 2013-09, Vol.50 (9), p.627-634

2013

Volltextzugriff (PDF)

AudioGene: Predicting Hearing Loss Genotypes from Phenotypes to Guide Genetic Screening

Human mutation, 2013-04, Vol.34 (4), p.539-545

2013

Volltextzugriff (PDF)

LGG-53. RESULTS FROM THE PHASE 1 AND PHASE 1 EXPANSION COHORTS OF SJ901: A PHASE 1/2 TRIAL OF SINGLE-AGENT MIRDAMETINIB (PD-0325901) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH LOW-GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Supplement_4), p.0-0

2024

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(32)
Buchkapitel
(3)

Sprache

Englisch
(35)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent model

Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats

Discovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists

Discovery of 4‑Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38

Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines

Discovery of Highly Potent and Selective Small Molecule ADAMTS‑5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT)

In Vitro Metabolism of Phenoxypropoxybiguanide Analogues in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines

Proteome-wide muscle protein fractional synthesis rates predict muscle mass gain in response to a selective androgen receptor modulator in rats

Identification and Characterization of 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a Selective and Irreversible Peroxisome Proliferator-Activated Receptor δ (PPARδ) Antagonist

Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method

Pharmacokinetics, Safety, and Hydrolysis of Oral Pyrroloquinazolinediamines Administered in Single and Multiple Doses in Rats

Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D 3 -creatine dilution method

Adenosine A1 Receptor Modulation of MMP-2 Secretion by Trabecular Meshwork Cells

The role of in vitro ADME assays in antimalarial drug discovery and development

Bradykinin enhancement of PGE2 signalling in bovine trabecular meshwork cells

Longitudinal determination of total body creatine pool size and skeletal muscle mass in rats by D 3 ‐creatine dilution

Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-d3) dilution in rats

Identification and Characterization of 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethylbenzamide (GSK3787), a Selective and Irreversible Peroxisome Proliferator-Activated Receptor δ (PPARδ) Antagonist

Bradykinin enhancement of PGE 2 signalling in bovine trabecular meshwork cells

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist

Utilizing Ethnic-Specific Differences in Minor Allele Frequency to Recategorize Reported Pathogenic Deafness Variants

Prediction of cochlear implant performance by genetic mutation: The spiral ganglion hypothesis

Advancing genetic testing for deafness with genomic technology

AudioGene: Predicting Hearing Loss Genotypes from Phenotypes to Guide Genetic Screening

LGG-53. RESULTS FROM THE PHASE 1 AND PHASE 1 EXPANSION COHORTS OF SJ901: A PHASE 1/2 TRIAL OF SINGLE-AGENT MIRDAMETINIB (PD-0325901) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH LOW-GRADE GLIOMA

Suchergebnisse filtern